

TRANSLATING THE NEW EVIDENCE IN THE MANAGEMENT OF TYPE 2 DIABETES

PLEASE JOIN US FOR A GROUP LEARNING SESSION!

DATE:

SPEAKER:

TIME:

LOCATION:

PROGRAM DESIGNED FOR A MULTIDISCIPLINARY AUDIENCE

PLANNING COMMITTEE MEMBERS

Peter Assimakopoulos
MD, FRCPC

Michael Boivin
BScPhm, RPh, CDE

Alice Y.Y. Cheng
MD, FRCPC

Jeremy Gilbert
MD, FRCPC

Jonathan Howlett
MD, FRCPC, FACC

Upender Mehan
MD, CCFP, FCFP

Anas Nseir
MD, CCFP, FCFP, B.Pharm

Kevin Saunders
MD, CCFP

This program will focus on antihyperglycemic selection for patients with and without cardiovascular disease based on evidence, including that published after the November 2016 Interim Update to the Diabetes Canada Clinical Practice Guidelines.

LEARNING OBJECTIVES

- Review the impact of underlying cardiovascular disease on antihyperglycemic selection
- Examine new evidence impacting antihyperglycemic selection since the November 2016 Interim Update to the Diabetes Canada Clinical Practice Guidelines
- Review the selection of antihyperglycemic medication for a patient without CVD who is not reaching glycaemic targets with metformin monotherapy
- Discuss the significance of CVD primary prevention results with antihyperglycemics

**JOIN
YOUR
PEERS**

Arrival time: **Location:**

Address:

PLEASE R.S.V.P. TO:

Email: **Cell:**



The Canadian Council on Continuing Education in Pharmacy has accredited this program for 1 CEU.

This program was supported by AstraZeneca